Global Relapsed Acute Myeloid Leukemia Drug Market Research Report 2021

Table of Contents

Global Relapsed Acute Myeloid Leukemia Drug Market Research Report 2021
1 Relapsed Acute Myeloid Leukemia Drug Market Overview
1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Relapsed Acute Myeloid Leukemia Drug Segment by Type (Product Category)
1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Production and CAGR (%) Comparison by Type (Product Category)(2016-2027)
1.2.2 Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Type (Product Category) in 2017
1.2.3 aNK Program
1.2.4 AT-9283
1.2.5 BI-836858
1.2.6 binimetinib
1.2.7 BL-8040
1.2.8 Others
1.3 Global Relapsed Acute Myeloid Leukemia Drug Segment by Application
1.3.1 Relapsed Acute Myeloid Leukemia Drug Consumption (Sales) Comparison by Application (2016-2027)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Relapsed Acute Myeloid Leukemia Drug Market by Region (2016-2027)
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size (Value) and CAGR (%) Comparison by Region (2016-2027)
1.4.2 North America Status and Prospect (2016-2027)
1.4.3 Europe Status and Prospect (2016-2027)
1.4.4 China Status and Prospect (2016-2027)
1.4.5 Japan Status and Prospect (2016-2027)
1.4.6 Southeast Asia Status and Prospect (2016-2027)
1.4.7 India Status and Prospect (2016-2027)
1.5 Global Market Size (Value) of Relapsed Acute Myeloid Leukemia Drug (2016-2027)
1.5.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue Status and Outlook (2016-2027)
1.5.2 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production Status and Outlook (2016-2027)

2 Global Relapsed Acute Myeloid Leukemia Drug Market Competition by Manufacturers
2.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production and Share by Manufacturers (2016-2021)
2.1.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity and Share by Manufacturers (2016-2021)
2.1.2 Global Relapsed Acute Myeloid Leukemia Drug Production and Share by Manufacturers (2016-2021)
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Share by Manufacturers (2016-2021)
2.3 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution, Sales Area and Product Type
2.5 Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation and Trends
2.5.1 Relapsed Acute Myeloid Leukemia Drug Market Concentration Rate
2.5.2 Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue (Value) by Region (2016-2021)
3.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity and Market Share by Region (2016-2021)
3.2 Global Relapsed Acute Myeloid Leukemia Drug Production and Market Share by Region (2016-2021)
3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Market Share by Region (2016-2021)
3.4 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
3.5 North America Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
3.6 Europe Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
3.7 China Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
3.8 Japan Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
3.9 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
3.10 India Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)

4 Global Relapsed Acute Myeloid Leukemia Drug Supply (Production), Consumption, Export, Import by Region (2016-2021)
4.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption by Region (2016-2021)
4.2 North America Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2016-2021)
4.3 Europe Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2016-2021)
4.4 China Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2016-2021)
4.5 Japan Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2016-2021)
4.7 India Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2016-2021)

5 Global Relapsed Acute Myeloid Leukemia Drug Production, Revenue (Value), Price Trend by Type
5.1 Global Relapsed Acute Myeloid Leukemia Drug Production and Market Share by Type (2016-2021)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Type (2016-2021)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2016-2021)
5.4 Global Relapsed Acute Myeloid Leukemia Drug Production Growth by Type (2016-2021)

6 Global Relapsed Acute Myeloid Leukemia Drug Market Analysis by Application
6.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption and Market Share by Application (2016-2021)
6.2 Global Relapsed Acute Myeloid Leukemia Drug Consumption Growth Rate by Application (2016-2021)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

7 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Profiles/Analysis
7.1 4SC AG
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.1.4 Main Business/Business Overview
7.2 AbbVie Inc.
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.2.4 Main Business/Business Overview
7.3 Actinium Pharmaceuticals, Inc.
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.3.4 Main Business/Business Overview
7.4 Agios Pharmaceuticals, Inc.
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.4.4 Main Business/Business Overview
7.5 Amgen Inc.
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2015-2021)
7.5.4 Main Business/Business Overview
7.6 Arog Pharmaceuticals, Inc.
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.6.4 Main Business/Business Overview
7.7 Array BioPharma Inc.
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.7.4 Main Business/Business Overview
7.8 Astellas Pharma Inc.
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.8.2.1 Product A
7.8.2.2 Product B
7.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.8.4 Main Business/Business Overview
7.9 Astex Pharmaceuticals, Inc.
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.9.2.1 Product A
7.9.2.2 Product B
7.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2021)
7.9.4 Main Business/Business Overview
7.10 AstraZeneca Plc
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
7.10.2.1 Product A
7.10.2.2 Product B
7.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2016-2020)
7.10.4 Main Business/Business Overview
7.11 AVEO Pharmaceuticals, Inc.
7.12 BioLineRx, Ltd.
7.13 Boehringer Ingelheim GmbH
7.14 Boston Biomedical, Inc.
7.15 Bristol-Myers Squibb Company
7.16 Calithera Biosciences, Inc.
7.17 Celgene Corporation
7.18 Cornerstone Pharmaceuticals, Inc.
7.19 CTI BioPharma Corp.

8 Relapsed Acute Myeloid Leukemia Drug Manufacturing Cost Analysis
8.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
9.1 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 Global Relapsed Acute Myeloid Leukemia Drug Market Forecast (2021-2027)
12.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue Forecast (2021-2027)
12.1.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production and Growth Rate Forecast (2021-2027)
12.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate Forecast (2021-2027)
12.1.3 Global Relapsed Acute Myeloid Leukemia Drug Price and Trend Forecast (2021-2027)
12.2 Global Relapsed Acute Myeloid Leukemia Drug Production, Consumption , Import and Export Forecast by Region (2021-2027)
12.2.1 North America Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2021-2027)
12.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2021-2027)
12.2.3 China Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2021-2027)
12.2.4 Japan Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2021-2027)
12.2.5 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2021-2027)
12.2.6 India Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2021-2027)
12.3 Global Relapsed Acute Myeloid Leukemia Drug Production, Revenue and Price Forecast by Type (2021-2027)
12.4 Global Relapsed Acute Myeloid Leukemia Drug Consumption Forecast by Application (2021-2027)

13 Research Findings and Conclusion

14 Appendix
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
List of Tables and Figures

Figure Picture of Relapsed Acute Myeloid Leukemia Drug
Figure Global Relapsed Acute Myeloid Leukemia Drug Production () and CAGR (%) Comparison by Types (Product Category) (2016-2027)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Types (Product Category) in 2017
Figure Product Picture of aNK Program
Table Major Manufacturers of aNK Program
Figure Product Picture of AT-9283
Table Major Manufacturers of AT-9283
Figure Product Picture of BI-836858
Table Major Manufacturers of BI-836858
Figure Product Picture of binimetinib
Table Major Manufacturers of binimetinib
Figure Product Picture of BL-8040
Table Major Manufacturers of BL-8040
Figure Product Picture of Others
Table Major Manufacturers of Others
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) by Applications (2016-2027)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Applications in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure Global Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD), Comparison (K Pcs) and CAGR (%) by Regions (2016-2027)
Figure North America Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2016-2027)
Figure Europe Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2016-2027)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2016-2027)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2016-2027)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2016-2027)
Figure India Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2016-2027)
Figure Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) Status and Outlook (2016-2027)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs) Status and Outlook (2016-2027)
Figure Global Relapsed Acute Myeloid Leukemia Drug Major Players Product Capacity (K Pcs) (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) of Key Manufacturers (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share of Key Manufacturers (2016-2021)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) of Key Manufacturers in 2017
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) of Key Manufacturers in 2021
Figure Global Relapsed Acute Myeloid Leukemia Drug Major Players Product Production (K Pcs) (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) of Key Manufacturers (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Production Share by Manufacturers (2016-2021)
Figure 2017 Relapsed Acute Myeloid Leukemia Drug Production Share by Manufacturers
Figure 2017 Relapsed Acute Myeloid Leukemia Drug Production Share by Manufacturers
Figure Global Relapsed Acute Myeloid Leukemia Drug Major Players Product Revenue (Million USD) (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Manufacturers (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2016-2021)
Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers
Table 2021 Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers
Table Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Manufacturers (2016-2021)
Figure Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Manufacturers in 2017
Table Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution and Sales Area
Table Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Category
Figure Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 Manufacturers
Figure Relapsed Acute Myeloid Leukemia Drug Market Share of Top 5 Manufacturers
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) by Region (2016-2021)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share by Region (2016-2021)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share by Region (2016-2021)
Figure 2017 Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share by Region
Table Global Relapsed Acute Myeloid Leukemia Drug Production by Region (2016-2021)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) by Region (2016-2021)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Region (2016-2021)
Figure 2017 Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Region
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Region (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2016-2021)
Figure Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2016-2021)
Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs) and Growth Rate (2016-2021)
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table North America Relapsed Acute Myeloid Leukemia Drug Cap

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.